Nubeqa™ (darolutamide) receives EU approval for additional indication in prostate cancer
Nubeqa™ (darolutamide) receives EU approval for additional indication in prostate cancer
Nubeqa™ (darolutamide) receives EU approval for additional indication in prostate cancer
Darolutamid i kombination med androgendeprivationsterapi och docetaxel ökar signifikant den totala överlevnaden hos patienter med metastaserad hormonkänslig prostatacancer.